Financials

Total revenue
Net income
Total debt
Free cash flow
Cash & equivalents

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
688
NBIX
Neurocrine Biosciences, Inc. - Common Stock
154.06 USD-1.19%+0.98%-13.93%+6.25%15.66 B USD
823
ELAN
Elanco Animal Health Incorporated Common Stock
24.12 USD-1.59%-0.74%-9.70%+7.70%12.05 B USD
1058
ALKS
Alkermes plc - Ordinary Shares
47.41 USD-3.05%-1.33%-0.92%+62.86%7.95 B USD
1158
LNTH
Lantheus Holdings, Inc. - Common Stock
100.77 USD+0.30%+0.67%+0.20%+79.75%6.58 B USD

Frequently asked questions about Dr. Reddy's Laboratories Limited American Depositary Shares

What is the Dr. Reddy's Laboratories Limited American Depositary Shares stock price today?

The current price of Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) is 12.18. Over the past 24 hours, the stock has changed by +0.25%. Follow the RDY chart for real-time price dynamics.

What is the stock ticker of Dr. Reddy's Laboratories Limited American Depositary Shares?

Dr. Reddy's Laboratories Limited American Depositary Shares trades under the ticker RDY. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Dr. Reddy's Laboratories Limited American Depositary Shares stock going up?

RDY has changed by -0.49% over the last week, +3.31% over the last month, and -14.23% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Dr. Reddy's Laboratories Limited American Depositary Shares?

Dr. Reddy's Laboratories Limited American Depositary Shares currently has a market capitalization of 10.17 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

Does Dr. Reddy's Laboratories Limited American Depositary Shares release financial reports?

Yes. You can track Dr. Reddy's Laboratories Limited American Depositary Shares financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.

How many employees does Dr. Reddy's Laboratories Limited American Depositary Shares have?

As of the latest available data, Dr. Reddy's Laboratories Limited American Depositary Shares has 27.53 K employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Dr. Reddy's Laboratories Limited American Depositary Shares stock?

You can buy Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Dr. Reddy's Laboratories Limited American Depositary Shares stock?

Investing in Dr. Reddy's Laboratories Limited American Depositary Shares requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the RDY chart and related analysis on metatrader.com as part of your research.

Dr. Reddy's Laboratories Ltd

Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr.

News